MXPA06009546A - Formulaciones solidas de ospemifeno. - Google Patents

Formulaciones solidas de ospemifeno.

Info

Publication number
MXPA06009546A
MXPA06009546A MXPA06009546A MXPA06009546A MXPA06009546A MX PA06009546 A MXPA06009546 A MX PA06009546A MX PA06009546 A MXPA06009546 A MX PA06009546A MX PA06009546 A MXPA06009546 A MX PA06009546A MX PA06009546 A MXPA06009546 A MX PA06009546A
Authority
MX
Mexico
Prior art keywords
further characterized
formulation according
drug formulation
drug
combinations
Prior art date
Application number
MXPA06009546A
Other languages
English (en)
Spanish (es)
Inventor
Veli-Matti Lehtola
Kaija Halonen
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34861126&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA06009546(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of MXPA06009546A publication Critical patent/MXPA06009546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA06009546A 2004-02-23 2005-01-19 Formulaciones solidas de ospemifeno. MXPA06009546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/783,024 US8642079B2 (en) 2004-02-23 2004-02-23 Solid formulations of ospemifene
PCT/FI2005/000037 WO2005079777A1 (en) 2004-02-23 2005-01-19 Solid formulations of ospemifene

Publications (1)

Publication Number Publication Date
MXPA06009546A true MXPA06009546A (es) 2007-04-10

Family

ID=34861126

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06009546A MXPA06009546A (es) 2004-02-23 2005-01-19 Formulaciones solidas de ospemifeno.

Country Status (19)

Country Link
US (2) US8642079B2 (https=)
EP (2) EP2286806A1 (https=)
JP (1) JP4993203B2 (https=)
CN (1) CN1953741B (https=)
AT (1) ATE506054T1 (https=)
AU (1) AU2005215174B2 (https=)
BR (1) BRPI0507897B8 (https=)
CA (1) CA2554695C (https=)
CY (1) CY1111689T1 (https=)
DE (1) DE602005027540D1 (https=)
DK (1) DK1718288T3 (https=)
ES (1) ES2364970T3 (https=)
MX (1) MXPA06009546A (https=)
NO (1) NO341573B1 (https=)
PL (1) PL1718288T3 (https=)
PT (1) PT1718288E (https=)
RU (2) RU2423113C2 (https=)
SI (1) SI1718288T1 (https=)
WO (1) WO2005079777A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891887B1 (ko) 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
DK1742618T3 (da) 2004-05-04 2012-10-01 Hormos Medical Ltd Flydende orale formuleringer af ospemifen
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101304738A (zh) * 2005-11-09 2008-11-12 霍尔莫斯医疗有限公司 非培米芬的制剂
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
CA2677861C (en) 2007-02-14 2015-05-19 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US7504530B2 (en) 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
WO2009123626A1 (en) * 2008-04-01 2009-10-08 Ocean 1 806, Llc Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
CN104788300B (zh) * 2014-01-22 2017-01-11 南京华威医药科技开发有限公司 欧司哌米芬多晶型
US20160000732A1 (en) * 2014-07-02 2016-01-07 Cadila Healthcare Limited Oral pharmaceutical compositions of ospemifene
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
US10138190B2 (en) 2015-01-09 2018-11-27 Glenmark Pharmaceuticals Limited Process for preparation of ospemifene
AU2016229086B2 (en) * 2015-03-10 2018-12-06 Shionogi Inc. Solid dispersions
US9750716B2 (en) * 2015-03-19 2017-09-05 Wendy Anne Epstein Compounds and forms of treatment for female sexual disorders
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20180206528A1 (en) * 2017-01-24 2018-07-26 Omnigen Research, Llc Granulated feed supplement and methods for making and using
RS63725B1 (sr) 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117121A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. Method of increasing bile flow and decreasing lipid levels
FI100692B (fi) 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5597582A (en) 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
AU718417B2 (en) * 1995-11-14 2000-04-13 Stockhausen Gmbh & Co. Kg Water additive and method for fire prevention and fire extinguishing
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
FI101305B1 (fi) 1996-03-18 1998-05-29 Map Medical Technologies Oy Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatsepiini-johdannaiset ja niiden käyttö diagnostiikassa
DE19653736C2 (de) * 1996-12-12 2002-11-21 Lancaster Group Gmbh Kosmetisches Präparat mit Peptidzusatz
RU2112504C1 (ru) * 1996-12-24 1998-06-10 Открытое акционерное общество "Нижегородский химико-фармацевтический завод" Средство для лечения заболеваний предстательной железы "витапрост"
US6525084B2 (en) * 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
AU5026599A (en) * 1998-07-23 2000-02-14 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
AU2002235348A1 (en) 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
RU2177802C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Тетрапептид, регулирующий функции предстательной железы, фармакологическое средство на его основе и способ его применения
US20030055075A1 (en) * 2001-07-13 2003-03-20 Rubsamen Reid M. Programmable controlled release injectable opioid formulation
DE60239207D1 (de) 2001-08-10 2011-03-31 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
SI1509215T1 (sl) 2002-06-06 2007-02-28 Hormos Medical Ltd Zdravljenje ali preprecevanje urogenitalne atrofije in njenih simptomov pri zenskah
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20060105045A1 (en) 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
EA010427B1 (ru) * 2007-04-27 2008-08-29 Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") Средство для лечения заболеваний предстательной железы
RU2430733C2 (ru) * 2009-10-08 2011-10-10 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения заболеваний предстательной железы (варианты)

Also Published As

Publication number Publication date
JP4993203B2 (ja) 2012-08-08
BRPI0507897B8 (pt) 2021-05-25
ES2364970T3 (es) 2011-09-19
EP2286806A1 (en) 2011-02-23
BRPI0507897B1 (pt) 2018-10-09
DE602005027540D1 (de) 2011-06-01
EP1718288A1 (en) 2006-11-08
US8642079B2 (en) 2014-02-04
JP2007523210A (ja) 2007-08-16
BRPI0507897A (pt) 2007-07-24
NO341573B1 (no) 2017-12-04
CA2554695C (en) 2013-03-05
AU2005215174A1 (en) 2005-09-01
RU2006133902A (ru) 2008-03-27
WO2005079777A1 (en) 2005-09-01
AU2005215174B2 (en) 2010-06-03
US20050187301A1 (en) 2005-08-25
CN1953741B (zh) 2011-03-30
DK1718288T3 (da) 2011-08-01
RU2423113C2 (ru) 2011-07-10
SI1718288T1 (sl) 2011-09-30
CN1953741A (zh) 2007-04-25
RU2011112362A (ru) 2012-10-10
US20140220118A1 (en) 2014-08-07
EP1718288B1 (en) 2011-04-20
PT1718288E (pt) 2011-07-25
ATE506054T1 (de) 2011-05-15
PL1718288T3 (pl) 2011-10-31
CA2554695A1 (en) 2005-09-01
RU2675624C2 (ru) 2018-12-21
NO20064262L (no) 2006-09-20
CY1111689T1 (el) 2015-10-07

Similar Documents

Publication Publication Date Title
US20140220118A1 (en) Solid formulations of ospemifene
EP3302565B1 (en) Solid dosage forms of palbociclib
JP2009542647A (ja) メマンチン医薬組成物
CN105935358B (zh) 一种沙库比曲缬沙坦缓释剂及其制备方法
US20060240101A1 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
US7045147B1 (en) Controlled release peroral compositions of levosimendan
JP6328138B2 (ja) Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
JP2023140859A (ja) アプレミラストを含有する錠剤の製造方法、アプレミラストを含有する錠剤、及びアプレミラストを含有する錠剤の打錠性の改善方法
HUP0105097A2 (en) Pharmaceutical mixtures comprising a combination of a profen and other active compounds
RU2441651C1 (ru) Способ получения фармацевтической композиции клозапина в виде таблеток и фармацевтическая композиция
KR20070032298A (ko) 오스페미펜의 고체 제제
US20090099142A1 (en) Pharmaceutical compositions comprising esterified estrogens and methyltestosterone and method of using same
KR20250129624A (ko) 갈란타민 미니정제
HK1034032B (en) Controlled release peroral compositions of levosimendan

Legal Events

Date Code Title Description
FG Grant or registration